ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating ...

Full-year sales for Roche’s diagnostics division were up by just 2% as the Big Pharma deals with ongoing challenges in China.  | Full-year sales for Roche’s diagnostics division were up by just 2% as ...

[28 January 2026]: Roche Diagnostics Middle East presented a landmark launch event revealing Accu-Chek SmartGuide, a ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Roche Holding (SWX:ROG) reported significant weight loss results from Phase II trials of its dual GLP-1/GIP obesity candidate ...

Roche (RHHBY) stock dips after 2025 results: sales, pharma & diagnostics growth, FX headwinds, and 2026 outlook.

Roche Holding reported positive Phase II results for its investigational obesity drug CT-388, showing robust efficacy and ...

Apollo Hospitals signs MoU with Roche Diagnostics India to advance digital innovation in clinical care at THIT 2026: Our Bureau, Mumbai Saturday, January 31, 2026, 14:15 Hrs [IST] ...

Roche Holding recently reported positive Phase II results for CT-388, its once-weekly dual GLP-1/GIP obesity drug candidate, ...

The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth ...

Revenue was largely in line with analyst expectations as Roche turns its attention to a diverse pipeline.

The cleanest case study of pharma and diagnostics operating as one strategic engine is Roche. Instead of treating diagnostics ...